title: Two patients with severe alcoholic hepatitis accompanied by hypercytokinemia and granulocytic hyperelastasemia, successfully treated by intravenous infusion of urinastarine (Miraclid).
abstract: Severe alcoholic hepatitis (SAH) is not simply a disease of the liver, but it also causes infection and multiple organ failure, and therefore carries an extremely poor prognosis. We report the successful treatment of two patients with SAH. Case 1: The patient was a 55-year-old man. He was a heavy drinker whose alcohol intake had increased for some 3 years to 1.8 L sake a day. Slight clouding of consciousness, fever, and jaundice were evident on his admission to our hospital. Laboratory data showed leukocytosis with a predominance of polymorphonuclear leukocytes, and a decline in coagulability. He tested negative for various hepatitis virus markers. With the diagnosis of SAH made, steroid pulse therapy and bilirubin adsorption therapy were administered. The jaundice improved and the interleukin-8 (IL-8) level decreased. Continuous intravenous infusion of urinastarine (Miraclid) normalized the granulocyte elastase level. Improvement was also seen in coagulability, ascites, icterus and consciousness. Case 2: The patient was a 49-year-old man. He was a heavy drinker whose alcohol intake had increased for 1 month. Fever, jaundice, ascites, and mild disturbance of consciousness were evident at the time of admission. Examination on admission diagnosed SAH. Bilirubin adsorption and continuous intravenous infusion of urinastarine were initiated. As a result, circulating IL-8 level was decreased and coagulability was improved. Therapy for granulocytic hyperelastasemia and hypercytokinemia supervening on SAH is a new effective approach on improvement in the disease.
authors.affiliation: Division of Gastroenterology, Niigata City General Hospital, Japan. june@qd5.so-net.ne.jp
authors.forename: K
authors.initials: K
authors.lastname: Furukawa
authors.forename: T
authors.initials: T
authors.lastname: Kamimura
authors.forename: Y
authors.initials: Y
authors.lastname: Mahune
authors.forename: H
authors.initials: H
authors.lastname: Ohota
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: N
authors.initials: N
authors.lastname: Ishihara
authors.forename: K
authors.initials: K
authors.lastname: Tazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Honda
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: I
authors.initials: I
authors.lastname: Miki
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: A
authors.initials: A
authors.lastname: Honma
mesh_terms: D001777:Blood Coagulation; D006023:Glycoproteins / Q000008:administration & dosage*; D006519:Hepatitis, Alcoholic / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous; D016209:Interleukin-8 / Q000097:blood*; D007958:Leukocyte Count; D019272:Leukocyte Elastase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D014361:Trypsin Inhibitors / Q000008:administration & dosage*
chemical_list: D006023:Glycoproteins; D016209:Interleukin-8; D014361:Trypsin Inhibitors; D019272:Leukocyte Elastase; C028665:urinastatin